Журнал «Почки» Том 14, №1, 2025

В огляді літератури аналізуються сучасні дані щодо фармакокінетики, фармакодинаміки прямих оральних антикоагулянтів, їх застосування при нефротичному синдромі, на різних стадіях хронічної хвороби нирок, обтяженої фібриляцією передсердь, венозними тромбозами, при коморбідній онкологічній патології.

The literature review analyzes current data on the pharmacokinetics, pharmacodynamics of direct oral anticoagulants, their use in nephrotic syndrome, at different stages of chronic kidney disease complicated by atrial fibrillation, venous thrombosis, and in comorbid oncological pathology.

прямі оральні антикоагулянти; апіксабан; дабігатран; едоксабан; нефротичний синдром; ривароксабан; тромбоемболії; тромбози; хронічна хвороба нирок

direct oral anticoagulants; apixaban; dabigatran; edoxaban; nephrotic syndrome; rivaroxaban; thromboembolism; thrombosis; chronic kidney disease

1. Qiu Z, Pang X, Xiang Q, Cui Y. The Crosstalk between Nephropathy and Coagulation Disorder: Pathogenesis, Treatment, and Dilemmas. JASN. 2023;34:1793-1811. doi.org/10.1681/ASN.0000000000000199.
2. Saeed Z, Sirolli V, Bonomini M, et al. Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients. Int. J. Mol. Sci. 2024;25:8705. doi.org/10.3390/ijms25168705.
3. Wu T, Tang LV, Hu Y. Venous Thromboembolism in Kidney Diseases and Genetic Predisposition. Kidney Dis. 2022;8:181-189. doi: 10.1159/000523777.
4. Wang SSY, Tang H, Ng H-Y, et al. Thromboembolic pheno–mena in patients with nephrotic syndrome: pathophysiology, risk factors, prophylaxis and treatment. British Journal of Hospital Medicine. 2024;85(1):1-10. https://doi.org/10.12968/hmed.2023.0354.
5. Barnes GD, Ageno W, Castellucci LA, et al. Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation. J Thromb Haemost. 2023;21(5):1381-1384. doi: 10.1016/j.jtha.2023.02.008.
6. Sánchez-Fuentes A, Rivera-Caravaca JM, López-Gálvez R, et al. Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics Frontiers in Cardiovascular Medicine. 2021;8:787235. https://doi.org/10.3389/fcvm.2021.787235.
7. Ashton V, Kerolus-Georgi S, Moore KT. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Po–pulations. J Clin Pharmacol. 2021;61(8):1010-1026. doi: 10.1002/jcph.1838.
8. Heestermans M, Poenou G, Hamzeh-Cognasse H, et al. Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells. 2022;11:3214. doi.org/10.3390/cells11203214.
9. Wilson A (Board Chair), Nicholl MC (Chief Executive). Clinical Excellence Commission, 2023, Direct Oral Anticoagulant (DOAC) Guidelines, October 2023, Sydney: Clinical Excellence Commission SHPN: (CEC) 230753. https://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0005/917807/DOAC-guidelines.pdf.
10. Qi X, Shao X (ed). Anticoagulation — An Update. Intech Open. 2024:166. https://www.intechopen.com/books/13034. DOI: 10.5772/intechopen.114188.
11. Levy JH, Shaw JR, Castellucci LA, et al. Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2024;22(10):2889-2899. doi.org/10.1016/j.jtha.2024.07.009.
12. Olie RH, Winckers K, Rocca B, Cate H. Oral Anticoagulants Beyond Warfarin. Annu. Rev. Pharmacol. Toxicol. 2024;64:551-575. doi: 10.1146/annurev-pharmtox-032823-122811.
13. Douxfils J, Ageno W, Samama C-M, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost. 2018;16(2):209-219. doi: 10.1111/jth.13912.
14. Willcox A, Ho L, Jones D. Implications of direct oral anticoagulation and antiplatelet therapy in intensive care. Crit Care Resusc. 2020;22(3):181-188. doi: 10.1016/S1441-2772(23)00384-8.
15. Exner T, Rigano J, Favaloro EJ. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays. Int J Lab Hematol. 2020;42(1):41-48. doi: 10.1111/ijlh.13196.
16. Moser KA, Smock KJ. Direct oral anticoagulant (DOAC) interference in hemostasis assays. Hematology. Am Soc Hematol Educ Program. 2021(1):129-133. doi: 10.1182/hematology.2021000241.
17. Margetić S, Goreta SŠ, Ćelap I, Razum M. Direct oral anticoagulants (DOACs): From the laboratory point of view. Acta Pharmaceutica. 2022;72:459-482. doi: https://doi.org/10.2478/acph-2022-0034.
18. Bejjani A, Khairani CD, Assi A, et al. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2024;83(3):444-465. doi.org/10.1016/j.jacc.2023.10.038.
19. Padrini R. Clinical Pharmacokinetics and Pharmacodyna–mics of Direct Oral Anticoagulants in Patients with Renal Failure. European Journal of Drug Metabolism and Pharmacokinetics. 2019;44:1-12. doi.org/10.1007/s13318-018-0501-y.
20. Atzemian N, Kareli D, Ragia G, et al. Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review. Front Pharmacol. 2023;29(14):1244098. doi: 10.3389/fphar.2023.1244098.
21. Russo V, Fabiani D. Put out the fire: The pleiotropic anti-inflammatory action of non-vitamin K oral anticoagulants. Pharmacological Research. 2022;182:106335. https://doi.org/10.1016/j.phrs.2022.106335.
22. Gori AM, Camilleri E, Bertelli A, et al. Pleiotropic effects of anti-thrombotic therapies: have direct oral anticoagulants any anti-inflammatory effect? Bleeding, Thrombosis and Vascular Biology. 2022;1:50. https://doi.org/10.4081/btvb.2022.50.
23. Jannati S, Patnaik R, Banerjee Y. Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants –(NOACs) in Inflammation and Protease-Activated Receptor Signaling. Int. J. Mol. Sci. 2024;25:8727. doi.org/10.3390/ijms25168727.
24. Mele M, Mele A, Imbrici P, et al. Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis. Molecules. 2024;29(11):2651. doi: 10.3390/molecules29112651.
25. Mezue K, Ram P, Egbuche O, et al. Anticoagulation-related nephropathy for the internist: a concise review. Am J Cardiovasc Dis. 2020;10(4):301-305. PMCID: PMC7675155.
26. Nonaka E, Takashima T, Matsumoto K, et al. Warfarin-related nephropathy: A case report of a delayed renal function improvement. Clin Case Rep. 2021;9:e04105. https://doi.org/10.1002/ccr3.4105.
27. Brittanee S, Matthew D, Gregory G. Warfarin Related Kidney Damage: A Confusing Case of Thrombophlebitis Masquerading as Infection. Journal of Primary Care & Community Health. 2023;14:1-3. doi.org/10.1177/21501319231159978.
28. Mitsuboshi S, Niimura T, Zamami Y, Ishizawa K. Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database. Br J Clin Pharmacol. 2021;87:2977-2981. https://doi.org/10.1111/bcp.14688.
29. Iwafuchi Y, Ito Y, Imai N, et al. Dabigatran-related Nephropathy Complicated by Tubulointerstitial Nephritis in a Patient with a Normal Renal Function and Undiagnosed IgA Nephropathy. Intern Med. 2024;63:1615-1621. doi: 10.2169/internalmedicine.2628-23.
30. Magbri A, Keshani B, Hernandez PA. Frequently Missed, Never Dismissed: Anticoagulant-Related Nephropathy. Open Journal of Nephrology. 2022;12:262-266. doi.org/10.4236/ojneph.2022.123027.
31. Piedade A, Domingues P, Inácio A, et al. Anticoagulant-related nephropathy: An atypical case with two episodes. NefroPlus. 2023;15(1):102-106. https://doi.org/10.1016/S1888-9700(24)00022-7.
32. Chen S, Liao D, Yang M, Wang S. Anticoagulant-related nephropathy induced by direct-acting oral anticoagulants: clinical cha–racteristics, treatments and outcomes. Thromb Res. 2022;222:20-23. doi: 10.1016/j.thromres.2022.12.002.
33. Dasgupta A, Mikhalina G, Satoskar AA, et al. Clinical Outcomes in Patients with Biopsy Proven Anticoagulant-Related Nephropathy. Kidney Int Rep. 2023;8:1445-1448. https://doi.org/10.1016/j.ekir.2023.04.014.
34. Wojtowicz D, Tomaszuk-Kazberuk A, Małyszko J, Koziński M. Hematuria and other kinds of bleedings on non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: an updated overview on occurrence, pathomechanisms and management. Wiadomości Lekarskie. 2020;73(11):2528-2534. doi: 10.36740/WLek202011135.
35. Bhatt NR, Davis NF, Nolan WJ, et al. Incidence of Visible Hematuria among Antithrombotic Agents: A Systematic Review of Over 175,000 Patients. Urology. 2018;114:27-32. doi: 10.1016/j.urology.2017.11.023.
36. Parker K, Ragy O, Hamilton P, et al. Thromboembolism in nephrotic syndrome: controversies and uncertainties. Research and Practice in Thrombosis and Haemostasis. 2023;7:6102162. https://doi.org/10.1016/j.rpth.2023.102162.
37. KDIGO Co-Chairs Jadoul M, Winkelmayer WC. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):S1-S276. doi: 10.1016/j.kint.2021.05.021.
38. Parker K, Choudhuri S, Lewis P, et al. UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey. BMC Nephrology. 2023;24:9. doi: 10.1186/s12882-022-03041-w.
39. Lin R, McDonald G, Jolly T, et al. A Systematic Review of Prophylactic Anticoagulation in Nephrotic Syndrome. Kidney Int Rep. 2020;5:435-447. https://doi.org/10.1016/j.ekir.2019.12.001.
40. Kelddal S, Hvas A-M, Grove EL, Birn H. Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: a report of 21 cases. BMC Nephrology. 2022;23:305. https://doi.org/10.1186/s12882-022-02929-x.
41. Van Meerhaeghe T, Cez A, Dahan K, et al. Apixaban prophylactic anticoagulation in patients with nephrotic syndrome. TH Open. 2022;6:e299-303. doi: 10.1055/a-1920-6224.
42. Tijani A, Coons EM, Mizuki B, et al. Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in patients with nephrotic syndrome:a retrospective cohort study. Ann Pharmacother. 2023;57:787-94. https://doi.org/10.1177/106002802211 29348.
43. Nissar SM, Kuchay AA, Mir TH, et al. Direct Oral Anticoagulants in Nephrotic Syndrome: Our Experience and Literature Review. Indian J Nephrol. 2024;34(2):169-171. doi: 10.4103/ijn.ijn_317_22.
44. Mullen DB, Di Renzo BM, Walroth TA, et al. Case Report: Possible Rivaroxaban Failure in Patient with Nephrotic Syndrome Discussing Anticoagulation in Nephrotic Syndrome. Clin Case Rep Int. 2021;5(1):1206. DOI: 10.25107/2638-4558.1206.
45. Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney International. 2020;97:664-675. doi: 10.1016/j.kint.2019.11.027.
46. Ktenopoulos N, Sagris M, Theofilis P, et al. Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse. Front. Biosci. (Schol Ed). 2022;14(3):21. https://doi.org/10.31083/j.fbs1403021.
47. Gadde S, Kalluru R, Cherukuri SP, et al. Atrial Fibrillation in Chronic Kidney Disease: An Overview. Cureus. 2022;14(8):e27753. doi: 10.7759/cureus.27753.
48. Yasuoka R, Sakurane H, Okune M, et al. Changes in estimated glomerular filtration rate before and after the first visit for atrial fibrillation. BMC Nephrology. 2024;25(9). https://doi.org/10.1186/s12882-023-03449-y.
49. Airy M, Schold JD, Jolly SE, et al. Cause-specific mortality in patients with chronic kidney disease and atrial fibrillation. Am J Nephrol. 2018;48:36-45. https://doi.org/10.1159/000491023.
50. Lucà F, Oliva F, Abrignani MG, et al. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios. J. Clin. Med. 2023;12:5955. https://doi.org/10.3390/jcm12185955.
51. KDIGO Co-Chairs Jadoul M, Grams ME. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4):S117-S314. doi: 10.1016/j.kint.2023.10.018.
52. Dhaese SAM, De Vriese AS. Oral Anticoagulation in Patients with Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation. Mayo Clin Proc. 2023;98(5):750-770. doi.org/10.1016/j.mayocp.2023.01.007.
53. De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrology Dialysis Transplantation. 2022;37(11):2072-2079. doi.org/10.1093/ndt/gfab060.
54. Heine GH, Brandenburg V, Schirmer SH. Oral anticoagulation in chronic kidney disease and atrial fibrillation — the use of non-vitamin K-dependent anticoagulants and vitamin K antagonists. Dtsch Arztebl Int 2018;115:287-94. doi: 10.3238/arztebl.2018.0287.
55. Albright RC Jr. Anticoagulating CKD Patients With Atrial Fibrillation: Are We Asking the Right Questions? Mayo Clin Proc. 2023;98(5):653-654. doi.org/10.1016/j.mayocp.2023.03.010.
56. Hirohiko TS, Fuchida MA, Takahiro TK, et al. Comparison of prognostic impact of anticoagulants in heart failure patients with atrial fibrillation and renal dysfunction: direct oral anticoagulants versus vitamin K antagonists. Heart and Vessels. 2022;37:1232-1241. doi.org/10.1007/s00380-022-02027-w.
57. Welander F. Anticoagulants in Kidney Disease. Umeå University, 2023; Umeå University medical dissertations (2261). https://umu.diva-portal.org/smash/get/diva2:1809670/FULLTEXT01.pdf.
58. Yao X, Inselman JW, Ross JS, et al. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients with Atrial Fibrillation. Circ. Cardiovasc. Qual. Outcomes. 2020;13:e006515. doi.org/10.1161/CIRCOUTCOMES.120.006515.
59. Harrington J, Carnicell AP, Hua K, et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From Combine AF. Circulation. 2023;147:1748-1757. doi: 10.1161/CIRCULATIONAHA.122.062752.
60. Li Y, Wu S, Zhou J, et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: a systematic review and meta-analysis. Thrombosis J. 2024;22:40. doi.org/10.1186/s12959-024-00608-5.
61. Chantrarat T, Hauythan S. The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation. IJC Heart & Vasculature. 2021;35:100844. doi.org/10.1016/j.ijcha.2021.100844.
62. Joglar JA (Chair), Chung MK (Vice Chair). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2024;83(1):109-279. doi.org/10.1016/j.jacc.2023.08.017.
63. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). European Heart Journal. 2024;45(36):3314-3414. https://doi.org/10.1093/eurheartj/ehae176.
64. Elenjickal EJ, Travlos CK, Marques P, Mavrakanas TA. Anticoagulation in Patients with Chronic Kidney Disease. Am J Nephrol. 2024;55(2):146-164. doi.org/10.1159/000535546.
65. Niehues P, Wolfes J, Wegner FK, et al. Use of direct oral anticoagulants in patients on chronic hemodialysis: Contemporary appraisal on the role for patients with atrial fibrillation. Trends Cardiovasc Med. 2024;34(7):446-450. doi.org/10.1016/j.tcm.2023.11.005.
66. Eikelboom J, loege JF, Thadhani R, et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney International. 2021;100:1199-1207. doi.org/10.1016/.kint.2021.08.028.
67. Welander F, Renlund H, Själander A. Risk factors for major bleeding in patients with atrial fibrillation and CKD G3–G5D on oral anticoagulants. Clinical Kidney Journal. 2024;17(8):sfae206. doi.org/10.1093/ckj/sfae206.
68. Barnes GD, Nunes JAW. Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations. Res Pract Thromb Haemost. 2024;8(2):102370. doi: 10.1016/j.rpth.2024.102370.
69. Kyriakoulis I, Adamou A, Stamatiou I, et al. Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis. European Journal of Internal Medicine. 2024;119:45-52. doi.org/10.1016/j.ejim.2023.08.020.
70. Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75:273-285. doi: 10.1016/j.jacc.2019.10.059.
71. Ballegaard ELF, Olesen JB, Kamperet A-L, et al. Oral anticoagulation for stroke prevention in atrial fibrillation and advanced kidney disease. Res Pract Thromb Haemost. 2024;8(2):102350. doi: 10.1016/j.rpth.2024.102350.
72. Kim D-G, Kim SH, Park SY, et al. Anticoagulation in patients with end-stage kidney disease and atrial fibrillation: a national po–pulation-based study. Clinical Kidney Journal. 2024;17(2):sfae029. https://doi.org/10.1093/ckj/sfae029.
73. Sinha T, Mayow AH, Abedin T, et al. Comparison of Effectiveness and Safety of Direct-Acting Oral Anticoagulants and Vitamin K Agonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. Cureus 2024;16(4):e57447. doi: 10.7759/cureus.57447.
74. Vallini V, Andreini R, Sibilia G, et al. Warfarin-induced calciphylaxis-related skin ulceration in patients with end-stage renal disease: case report and literature review. Journal of Wound Care. 2024;33(8):13. doi.org/10.12968/jowc.2022.0218.
75. Rupinder K, Sindhu Y, Saikiran M, et al. A Difficult Case of Calciphylaxis: Continuous Warfarin Use in a Patient with Calciphylaxis. Journal of the American Society of Nephrology. 2024;35(10S):10.1681. doi: 10.1681/ASN.20242mq9jr6z.
76. Alasmari MM, Alsheikh MY, Metwali HH. Successful Treatment Using Apixaban in a Patient on Hemodialysis with Uremic Calciphylaxis. Clinical, Cosmetic and Investigational Dermatology. 2022;15:2329-2333. doi: 10.2147/CCID.S382503.
77. Chen C, Cao Y, Zheng Y, et al. Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4–5 Chronic Kidney Disease or on Dialysis. 2021;35:273-281. doi: 10.1007/s10557-021-07144-8.
78. Chandrasegaram A, Peters CD. The use of non-vitamin K oral anticoagulants in dialysis patients — A systematic review. Semin Dial. 2022;35(6):463-480. https://doi.org/10.1111/sdi.13098.
79. Law MM, Tan S-J, Wong MCG, Toussaint ND. Atrial Fibrillation in Kidney Failure: Challenges in Risk Assessment and Anticoagulation Management. Kidney Med. 2023;5(9):100690. doi: 10.1016/j.xkme.2023.100690.
80. Kessler A, Kolben Y, Puris G, et al. Direct Oral Anticoagulants in Special Patient Populations. J. Clin. Med. 2024;13:216. doi.org/10.3390/jcm13010216.
81. Weber J. Olyaei A. Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature. Eur J Haematol. 2019;102:312-318. doi: 10.1111/ejh.13208.
82. Fu EL, Desai RJ, Paik JM, et al. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients with Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study. Am J Kidney Dis. 2024;83(3):293-305. doi: 10.1053/j.ajkd.2023.08.017.
83. Mavrakanas TA, Garlo K, Charytan DM. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol. 2020;15(8):1146-1154. doi: 10.2215/CJN.11650919.
84. Reinecke H, Engelbertz C, Bauersachs R, et al. A Rando–mized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Сirculation. 2022;147(4):296-309. doi.org/10.1161/CIRCULATIONAHA.122.062779.
85. Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol. 2019;14:278-287. doi.org/10.2215/CJN.02170218.
86. Goto S, Haas S, Ageno M, et al. Assessment of Outcomes Among Patients With Venous Thromboembolism with and without Chronic Kidney Disease. JAMA Network Open. 2020;3(10):e2022886. doi: 10.1001/jamanetworkopen.2020.22886.
87. Zhan Y, Fu X, Bi W, Li G. Risk factors for venous thromboembolism in patients with chronic kidney disease: a systematic review and meta-analysis. Renal Failure. 2024;46(2): 2431149. doi.org/10.1080/0886022X.2024.2431149.
88. Singh J, Khadka S, Solanki D, et al. Pulmonary embolism in chronic kidney disease and end-stage renal disease hospitalizations: Trends, outcomes, and predictors of mortality in the United States. SAGE Open Med. 2021;3(9):20503121211022996. doi: 10.1177/20503121211022996.
89. Becattini C, Bauersachs R, Maraziti G, et al. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. 2022;107(7):1567-1576. doi.org/10.3324/haematol.2021.279072.
90. Morán LO, José F, Mateo P, et al. SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023). Clin Transl Oncol. 2024;26(11):2877-2901. doi: 10.1007/s12094-024-03605-2.
91. Cohena AT, Noxonb V, Dhamanec AD, et al. Effectiveness and safety of anticoagulants among patients with venous thromboembolism and active cancer who also had prior bleed or prior renal di–sease. Current Medical Research and Opinion. 2024;40(3):545-553. doi.org/10.1080/03007995.2024.2313092.
92. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7.